Kazia Therapeutics Limited
KZIA
$13.16
-$0.67-4.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 26.70K | 26.70K | 26.70K | 773.70K | 1.52M |
| Total Other Revenue | 1.18M | 1.16M | 1.13M | 625.30K | 128.70K |
| Total Revenue | 1.21M | 1.18M | 1.16M | 1.40M | 1.65M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.21M | 1.18M | 1.16M | 1.40M | 1.65M |
| SG&A Expenses | 7.90M | 6.75M | 5.67M | 7.48M | 9.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.10M | 11.71M | 10.42M | 15.56M | 20.73M |
| Operating Income | -11.89M | -10.53M | -9.26M | -14.16M | -19.08M |
| Income Before Tax | -15.74M | -15.07M | -14.52M | -16.68M | -18.91M |
| Income Tax Expenses | -1.02M | -1.07M | -1.11M | -639.30K | -178.70K |
| Earnings from Continuing Operations | -14.72 | -14.01 | -13.41 | -16.04 | -18.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.72M | -14.01M | -13.41M | -16.04M | -18.73M |
| EBIT | -11.89M | -10.53M | -9.26M | -14.16M | -19.08M |
| EBITDA | -11.24M | -9.73M | -8.30M | -13.04M | -17.85M |
| EPS Basic | -3.74K | -5.08K | -6.48K | -10.40K | -14.34K |
| Normalized Basic EPS | -3.21 | -5.10 | -7.07 | -12.86 | -18.65 |
| EPS Diluted | -3.74K | -5.08K | -6.48K | -10.40K | -14.34K |
| Normalized Diluted EPS | -3.21 | -5.10 | -7.07 | -12.86 | -18.65 |
| Average Basic Shares Outstanding | 8.92M | 6.65M | 4.38M | 3.62M | 2.85M |
| Average Diluted Shares Outstanding | 17.60K | 13.10K | 8.60K | 7.10K | 5.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |